Lo
Loxo (Lilly)
Stamford CTFounded 2013100 employees
Private CapbiotechAcquiredOncology
Platform: Larotrectinib TRK
Market Cap
N/A
All Drugs
3
Clinical Trials
3
Failed / Terminated
0
FDA Approved
0
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| Nirasertib | LOX-7044 | Phase 2 | 1 | CD20 | DMDPsoriasis | ||
| Kemanesiran | LOX-3138 | Phase 1 | 1 | GLP-1R | Wet AMDRett | ||
| Rimanesiran | LOX-2492 | Phase 3 | 1 | BET | DMDMDD |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (3)